Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PTC Therapeutics ( (PTCT) ) has shared an update.
On April 28, 2026, PTC Therapeutics reported positive 24‑month interim data from the PIVOT‑HD long‑term extension study of votoplam in Huntington’s disease, showing a dose‑dependent slowing of disease progression in Stage 2 patients versus a matched natural history cohort. Patients receiving the 10 mg dose achieved a 52% reduction in progression on the Composite Unified Huntington’s Disease Rating Scale, supported by favorable biomarker trends and a safety profile at Month 24 consistent with earlier findings.
The results strengthen the clinical rationale for Novartis’s global Phase 3 INVEST‑HD trial, which has been initiated to enroll about 770 early‑stage Huntington’s disease patients on 10 mg votoplam or placebo over up to 36 months. The encouraging efficacy signals and safety data reinforce PTC’s and Novartis’s positioning in the race to develop a disease‑modifying therapy for Huntington’s disease, a field with no approved treatments that slow progression, and may enhance the asset’s strategic and commercial potential if confirmed in Phase 3.
The most recent analyst rating on (PTCT) stock is a Hold with a $75.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
Spark’s Take on PTCT Stock
According to Spark, TipRanks’ AI Analyst, PTCT is a Neutral.
The score is driven mainly by improved profitability and strong free-cash-flow generation, plus upbeat 2026 growth guidance and strong Sephience launch execution. These positives are tempered by elevated balance-sheet risk from negative equity, mixed technical momentum, and regulatory/product headwinds (notably Translarna and vatiquinone), despite a relatively low P/E valuation.
To see Spark’s full report on PTCT stock, click here.
More about PTC Therapeutics
PTC Therapeutics, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing clinically differentiated medicines for children and adults with rare disorders. The company advances a diversified pipeline of treatments targeting unmet medical needs, leveraging its scientific platforms and global commercial infrastructure to build value in specialty genetic diseases and neurology.
Average Trading Volume: 1,095,406
Technical Sentiment Signal: Buy
Current Market Cap: $5.65B
See more insights into PTCT stock on TipRanks’ Stock Analysis page.